Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	8/8/2018 10:51:24 AM
	of 3559

REGN 2Q pps gains did not last long....long feared Eylea price control by CMC part B involvement (this time by Medicare Advantage plus program for part B drugs) is surfacing again. In my speculative calculation, IF there is 10% reduction in Eylea price, it would be ~$260M lost Eylea US revenue in 2020. Does this justify $4B lost in EV (MC) judge for yourself! Cheers, Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next